TABLE 3.

MIC result variations and summary of essential agreement rates between dry-form broth microdilution formulation panel (Sensititre) and revised reference method for telavancin

^an, no. of isolates tested.

^bPreviously established BMD panels prepared with DMSO and water as the solvent and diluent, respectively, and no P-80 supplementation versus a revised BMD panel (DMSO as solvent and diluent and P-80 supplementation [0.002%]).

^cPercentage of essential agreement (±1 log₂ dilution step), represented by the shaded area.

^dCoNS, coagulase-negative staphylococci.

^eIncludes 20 VRE (15 VanA and 5 VanB phenotypes).

^fIncludes 23 VRE (17 VanA and 6 VanB phenotypes).

^gBHS, beta-hemolytic streptococci.

^hVGS, viridans group streptococci.

ⁱRepresent strains with key resistance phenotypes (11 hVISA, 5 VISA, 6 VRSA, 10 VRE, 13 daptomycin-nonsusceptible staphylococci, and 11 linezolid-resistant staphylococci).